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Monosomy 1p36 is considered the most common subtelomeric deletion syndrome in humans and it accounts for 0.5–0.7% of all
the cases of idiopathic intellectual disability. The molecular diagnosis is often made by microarray-based comparative genomic
hybridization (aCGH), which has the drawback of being a high-cost technique. However, patients with classic monosomy 1p36
share some typical clinical characteristics that, together with its common prevalence, justify the development of a less expensive,
targeted diagnostic method. In this study, we developed a simple, rapid, and inexpensive real-time quantitative PCR (qPCR) assay
for targeted diagnosis of monosomy 1p36, easily accessible for low-budget laboratories in developing countries. For this, we have
chosen two target genes which are deleted in the majority of patients with monosomy 1p36: PRKCZ and SKI. In total, 39 patients
previously diagnosedwithmonosomy 1p36 by aCGH, fluorescent in situ hybridization (FISH), and/ormultiplex ligation-dependent
probe amplification (MLPA) all tested positive on our qPCR assay. By simultaneously using these two genes we have been able to
detect 1p36 deletions with 100% sensitivity and 100% specificity. We conclude that qPCR of PRKCZ and SKI is a fast and accurate
diagnostic test for monosomy 1p36, costing less than 10US dollars in reagent costs.
1. Introduction
Monosomy 1p36 (OMIM #607872) is one of the most
common chromosome abnormalities in humans, affecting
approximately 1 in 5,000 live births. It is considered the
most common subtelomeric deletion syndrome in humans,
resulting from a heterozygous deletion of the most distal
chromosomal band on the short arm of chromosome 1 [1–
3]. Monosomy 1p36 is generally sporadic [2] and is believed
to account for 0.5–0.7% of all cases of idiopathic intellectual
disability. Several mechanisms may be involved in the gener-
ation and/or stabilization of the rearrangements in the 1p36
region, whichmay include terminal and interstitial deletions,
derivative chromosomes, andmore complex rearrangements,
but the major mechanism stabilizing terminal deletions
appears to be breakage-fusion-bridge (BFB) cycles [4]. There
are no common breakpoints and the deletion sizes vary from
<1Mb to >10Mb [2, 3, 5–8].Themajority of the patients with
monosomy 1p36 have large terminal deletions [3], generally
found within the first 4-5Mb from the 1p telomere [2, 5, 7].
Patients with classic monosomy 1p36, who represent
the majority of cases reported in the literature, have some
typical clinical characteristics, with a phenotype that has
been incorporated into standard malformation syndrome
atlases [9]. It involves developmental delay and intellectual
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disability, both generally severe to profound, hypotonia and
feeding problems in infancy and characteristic dysmorphic
facial features which include: microcephaly, large late-closing
anterior fontanelle, deep-set eyes, broad nasal bridge, straight
eyebrows, and pointed chin [2, 9, 10]. Other features in
some individuals include seizures, hearing loss, structural
heart defects, cardiomyopathy, and behavior abnormalities.
Some recent studies have reported the identification of a
small proportion of patients with atypical “expanded” 1p36
phenotype, making the differential diagnosis difficult [11, 12];
however, according to Giannikou et al. [12], in these cases,
the coexistence of additional “copy number variants” (CNVs)
elsewhere in the genome may affect and explain partially or
completely the variability of their clinical phenotype.
The laboratory validation of the clinical diagnosis is
essential for establishing a medical prognosis and providing
genetic counseling to the family. Since many 1p36 dele-
tions are not able to be visualized by light microscopy, the
molecular confirmation nowadays is most often achieved
by microarray-based comparative genomic hybridization
(aCGH). However, the high cost of this test limits its broad
adoption, especially in developing countries [13].
Since a characteristic phenotype has been defined, mono-
somy 1p36 is amenable to targeted molecular diagnosis. For
that, we felt that real-time quantitative PCR (qPCR) met the
requirements of cost-effectiveness and easy execution [13–
18]. Thus, we report the development of a sensitive, rapid,
and affordable qPCR diagnostic method for monosomy 1p36,
using two target genes which are deleted in the majority of
patients with monosomy 1p36: PRKCZ and SKI. Using such
double-pronged methodology we have been able to detect,
with 100% sensitivity and 100% specificity, the 1p36 deletion
in 39 patients who had been previously diagnosed by aCGH,
fluorescent in situ hybridization (FISH), and/or multiplex
ligation-dependent probe amplification (MLPA).
2. Material and Methods
2.1. Subjects. We studied 39 patients previously diagnosed
with monosomy 1p36 (“Positive Group”; 11 males and 28
females). Twenty-eight patients (7 males and 21 females) had
the diagnosis confirmed by aCGHat SignatureGenomic Lab-
oratories (Spokane, WA, USA). Some samples were tested
by whole-genome, bacterial artificial chromosome-basedmi-
croarray (SignatureChipWG, Signature Genomic Laborato-
ries, Spokane, WA, USA) according to previously described
methods [19], while others were analyzed by whole-genome,
oligonucleotide-based microarrays custom-designed by Sig-
nature Genomics (SignatureChipOS, either version 1, a 105K-
feature array manufactured by Agilent Technologies, Santa
Clara, CA, USA, or version 2, a 135K-feature array manufac-
tured by Roche NimbleGen, Madison, WI, USA) according
to previously described methods [20, 21]. Ten patients (4
males and 6 females) were diagnosed using the techniques
of FISH and/or MLPA, according to previously described
methods [8], with addition of SALSAMLPA kit P070Human
Telomere-5probemix (MRC-Holland,http://www.mlpa.com/).
This step was carried out at Unidade de Aconselhamento
Gene´tico of the Centro de Estudos do Genoma Humano
of Universidade de Sa˜o Paulo (Instituto de Biocieˆncias,
Departamento de Gene´tica e Biologia Evolutiva, USP). One
patient (male) was commercially diagnosed by aCGH at the
Cytogenetics andMolecularDiagnostics Laboratory (Univer-
sity of Miami, Miami, FL, USA). As controls, we ran DNA
from 50 normal patients (“Normal Controls”; 25 males and
25 females) from GENE-Nu´cleo de Gene´tica Me´dica.
2.2. Ethics Statement. A written consent, approved by the
Ethics Committee on Research on Humans of the Instituto
de Biocieˆncias of Universidade de Sa˜o Paulo (CEP-IB-USP),
was obtained from the guardians of ten patients with mono-
somy 1p36 for using their genetic material. Two patients
with monosomy 1p36 were enrolled in a research study on
chromosome abnormalities approved by the Institutional
Review Board Spokane. DNA samples from other partici-
pants with monosomy 1p36 were obtained from diagnostic
procedures prior and anonymized prior to research use,
without requiring specific ethics committee approval. This
study was conducted in accordance with the principles of the
Declaration of Helsinki.
2.3. Real-Time Quantitative PCR (qPCR). The qPCR assays
for monosomy 1p36 were performed with two target genes:
PRKCZ (protein kinase C, zeta) and SKI (v-ski avian sarcoma
viral oncogene homolog). The primers used for amplifi-
cation of both markers were designed using the Primer3
program, version 0.4.0 (http://frodo.wi.mit.edu/).The primer
sequences were aligned against the entire human genome
using the UCSC program (http://www.genome.ucsc.edu/).
This step was performed to ensure that the primers amplified
only the genomic region of interest and also to guarantee that
the forward and reverse primers were free of single nucleotide
polymorphisms (SNPs).TheHMBSmarker (hydroxymethyl-
bilane synthase) was chosen as reference gene, and the
primer sequences used for its amplificationwere derived from
Saugier-Veber et al. [22], without the addition of the universal
extension cited by the authors.The primer sequences and the
sizes of the amplicons are shown in Table 1.
Each qPCR reaction contained 5 𝜇L of SYBR Green PCR
Master Mix 2X (Applied Biosystems, Foster City, CA, USA);
10 ng of genomic DNA; forward and reverse primers at
optimized concentrations; and sterile water up to a final
volume of 10 𝜇L. The reaction profile was an initial step
of 50∘C for 2min and a step of denaturation at 95∘C for
10min, followed by 50 cycles of denaturation at 95∘C for 15 sec
and combined annealing and extension at 60∘C for 60 sec.
All the samples were subjected to gradual denaturation to
determine the melting curve after 50 amplification cycles.
A “no template control” (NTC) was made in all the qPCR
reactions for each pair of primers containing all the reagents
except DNA. The qPCR reactions were performed using
Rotor-Gene Q (Qiagen Inc, Valencia, CA, USA) equipment,
and the data were processed by the associated Rotor-Gene Q
Series Software, version 1.7 (build 94) (Qiagen Inc, Valencia,
CA, USA).
The optimum concentration of each primer was deter-
mined by an initial test called concentration test of primers.
The concentrations tested were 0.1, 0.2, 0.3, 0.4, and 0.6𝜇M.
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Table 1: qPCR primer sequences, genomic location, and size of each amplicon.
Marker Chr Primer name Sequence (5󸀠 → 3󸀠) Amplicon size Genomic location of amplicon (hg19)
PRKCZa 1 PRKCZ-F ACGGTGTGAGCATGAGGATAC
c
125 2,020,732-2,020,856
PRKCZ-R CAGAGGCTGAAGCAAATGAACc
SKIa 1 SKI-F AGCTGATTGGGGGTAGGC
c
85 2,221,777-2,221,861
SKI-R TCAGGCTGAGCAGTGCAGc
HMBSb 11 HMBS-F ACGGCTCAGATAGCATACAAG
d
185 118,963,676-118,963,860
HMBS-R ATGCCTACCAACTGTGGGTCAd
Chr: chromosome; atarget gene; breference gene; cprimer sequences designed using Primer3 software, version 0.4.0 (http://frodo.wi.mit.edu/); dprimer
sequences derived from Saugier-Veber et al. [22].
From this test, the concentrations of each forward (F) and
reverse (R) primer to be used in qPCR reactions were
standardized in 0.1𝜇M(F)/0.1 𝜇M(R) forHMBS and SKI and
0.2 𝜇M (F)/0.2𝜇M (R) for PRKCZ.
Standard curves for all the primer sets were generated
with series of log dilution of genomic DNA: 20, 10, 5, and
2.5 nM for HMBS and 101, 100, 10−1, and 10−2 nM for PRKCZ
and SKI. Each dilution was tested in triplicate. Slopes derived
from standard curves were used to calculate the efficiency
of the qPCR reaction for each marker and also to normalize
qPCR data. Reaction specificity was confirmed with melting
curves analysis and polyacrylamide gel electrophoresis exper-
iments.
A negative control sample was used in all the qPCR runs.
This negative control corresponds to the DNA of an individ-
ual who is not affected by monosomy 1p36. The presence of
the negative control in each qPCR run is fundamental for the
final calculation of copy number change of each marker.
2.4. Analysis of the qPCR Data. The equations used for
normalization of the qPCR data and for the calculation of
the allelic copy number of each marker were derived from
studies of Weksberg et al. [13] and Hughes et al. [17]. The
D’Agostino-Pearson test for normal distribution of the values
of fold copy number change (ΔKCt) and ROC curve (receiver
operating characteristic curve) analyzes were made using
MedCalc software, version 12.2.1 (MedCalc Software, Mari-
akerke, Belgium). The measures used to assess the accuracy
of qPCR in discriminating between the group of normal
controls and the positive group were sensitivity, specificity,
and area under the ROC curve (AUC). For each marker a dot
plot was also obtained using MedCalc software.
3. Results
Polyacrylamide gel electrophoresis experiments (data not
shown) and melting curve analyzes confirmed the specificity
of the qPCR assays for amplification of the reference gene
(HMBS) and of the two target genes (PRKCZ and SKI) (see
Figures 1(a), 1(b), and 1(c) for melting curve of, resp., HMBS,
PRKCZ, and SKI).
The qPCR reactions occurred with high efficiency (great-
er than 94%), with R2 values of the standard curve greater
than 0.99 (Table 2).
Table 2: Slope, amplification efficiency, and R2 values for all the
markers.
Marker Slope Amplification efficiency R2
PRKCZa −3.1950 94.42% 0.9981
SKIa −3.1910 94.23% 0.9975
HMBSb −3.4350 95.49% 0.9964
R2: determination coefficient; atarget gene; breference gene.
The calculation of ΔKCt for PRKCZ and SKI was per-
formed considering the groups “Normal Controls” (Sup-
plementary Table 1, available online at http://dx.doi.org/
10.1155/2014/836082) and “Positive Group” (Supplementary
Table 2). Table 3 shows an overview of the ΔKCt results for
the two above groups. The value of the mean ΔKCt ± SD for
the normal controls was near zero for both markers: PRKCZ
(−0.0612±0.1554) and SKI (−0.1264±0.1401), indicating the
presence of two allelic copies of each marker (Table 3).
The value of the mean ΔKCt ± SD for the positive group
was near −1.000 for the two markers: PRKCZ (−0.9696 ±
0.1649) and SKI (−1.0287 ± 0.2880) (Table 3). The maximum
value ofΔKCt for PRKCZ in the positive group (−0.6676) was
lower than theminimumvalue ofΔKCt obtained in the group
of normal controls (−0.3661), showing a complete separation
of PRKCZ results between the two groups (Table 3). These
results show that the 39 patients have hemizygous microdele-
tion of PRKCZ, which in turn is sufficient to identify them as
having monosomy 1p36.
In the analysis of the SKI marker, one of the patients
(subject 11 of Supplementary Table 2) showed a ΔKCt value
near zero (−0.2876), corresponding to the maximum value
of ΔKCt obtained for this marker in the positive group
(Table 3). This result of ΔKCt was located in the normal
range for the SKI marker (Table 3). However, this patient
presented clear hemizygosity of PRKCZ (ΔKCt = −1.2278),
confirming the presence of monosomy 1p36 (Supplementary
Table 2). Equal results had been previously obtained byMLPA
(data not shown). ΔKCt results of the SKI marker for the
remaining 38 patients (−0.5479 to −1.5803) were lower than
the minimum value of ΔKCt obtained in the group of normal
controls (−0.3794), showing a complete separation of SKI
results between the 38 patients and the 50 normal controls
(Table 3).
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Table 3: Overview of the qPCR markers results.
Sample types Marker 𝑛 ΔKCt
Mean SD Median Maximum Minimum
Normal controls PRKCZ 50 −0.0612 0.1554 −0.0533 0.3551 −0.3661
SKI 50 −0.1264 0.1401 −0.1514 0.1956 −0.3794
Positive group PRKCZ 39 −0.9696 0.1649 −0.9634 −0.6676 −1.2644
SKI 39 −1.0287 0.2880 −1.0710 −0.2876a −1.5803
ΔKCt: fold copy number change; 𝑛: sample size; SD: standard deviation.
ΔKCt results (expressed as mean ΔKCt ± SD) consistent with the loss of one allelic copy are indicated in bold.
a
ΔKCt result obtained for patient 11 (subject 11 of Supplementary Table 2), indicative of nondeletion of SKI gene.This patient presented hemizygosity of PRKCZ
(ΔKCt = −1.2278), confirming that he has monosomy 1p36. Equal results were obtained by MLPA (data not shown). The remaining 38 patients had ΔKCt
results corresponding to hemizygous microdeletion of SKI (−0.5479 to −1.5803) and PRKCZ (−0.6676 to −1.2644).
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Figure 1:Melting curve for themarkers: (a)HMBS, (b) PRKCZ, and (c) SKI. All themarkers showed the presence of a single dissociation peak
and absence of primer dimers.The melting temperature of each amplicon was:HMBS: 𝑇
𝑚
= 82.6
∘C; PRKCZ: 𝑇
𝑚
= 85.2
∘C; SKI: 𝑇
𝑚
= 85.6
∘C.
NTC: No template control.These results were obtained using the Rotor-Gene Q Series Software, version 1.7 (build 94) (Qiagen Inc., Valencia,
CA, USA).
The results described above were corroborated by statisti-
cal analyzes made using the MedCalc software, version 12.2.1
(MedCalc Software, Mariakerke, Belgium). The ΔKCt values
for both markers in the group of normal controls presented
normal distribution according to D’Agostino-Pearson test
(data not shown). The detection performance of the primers
was evaluated using ROC curve analyzes.
Using the ΔKCt values of the negative (normal controls)
and positive groups (Supplementary Tables 1 and 2) and
considering that the qPCR approach of this study is a double-
pronged methodology, the simultaneous use of PRKCZ and
SKI markers in qPCR assays produced a ROC curve with
AUC equal to 1.000 (95%CI, 0.959–1.000) and corresponding
𝑃 value equal to zero.This confirms that the qPCR technique
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Figure 2: Dot plot for the markers which were analyzed in the study of monosomy 1p36: (a) PRKCZ and (b) SKI. ΔKCt (fold copy number
change) values of the 50 normal controls and of the 39 patients with monosomy 1p36 were considered for construction of the dot plot. The
threshold value (Thres) is shown inside of each graph. On the horizontal axis (Diagnosis), the number 0 represents the negative group (normal
controls) and the number 1 represents the positive group. Each individual is represented by a circle within the graph.Thehorizontal linewithin
the graph indicates the threshold value, which corresponds to the ΔKCt value chosen as limit of separation between the two groups. ΔKCt
result obtained for patient 11 is indicated by a black arrow in both graphs.This patient does not have deletion of SKI (ΔKCt = −0.2876), but he
presents hemizygous deletion of PRKCZ (ΔKCt = −1.2278), confirming that he has monosomy 1p36. Equal results were previously obtained
byMLPA.The simultaneous use of these two genes in the qPCR assays resulted in a test with 100% sensitivity and 100% specificity.The graphs
were obtained using MedCalc software, version 12.2.1 (MedCalc Software, Mariakerke, Belgium).
was capable to differentiate between an individual who has
a hemizygous microdeletion in 1p36 region and a normal
individual. And by using these two genes we achieved a test
with 100% sensitivity (95% CI, 91.0–100.0) and 100% speci-
ficity (95% CI, 92.9–100.0) (Figure 2). The threshold value
for each marker, which was chosen as the limit of separation
between the positive and negative groups, is shown in
Figure 2.
All results obtained for monosomy 1p36 using the qPCR
techniquewere also previously observed using othermethods
of analyzes (aCGH, FISH, and MLPA). For the majority
of the patients it was possible to determine that both
PRKCZ and SKI genes were deleted using the techniques
described above. In the specific case of patient 10 there was
a difference in the results obtained for the SKI gene specif-
ically. According to previous MLPA data, patient 10 had an
unbalanced translocation between subtelomeric regions of
1p and 7q, presenting a 1p36 deletion of ∼1.9–2.2Mb and a
7q duplication, the size of which has not been determined
(data not shown). Moreover, the MLPA analysis showed that
the deletion breakpoint in this patient occurred somewhere
within the 281 kb interval, between the genomic coordi-
nates chr1:1,956,418-2,237,544, according to UCSC Genome
Browser, Human February 2009 Assembly (GRCh37/hg19;
http://www.genome.ucsc.edu/). Of note, the MLPA probe
specific for the SKI gene remained intact in this patient,
while the qPCR results showed deletion of both PRKCZ
(ΔKCt = −1.1885) and SKI (ΔKCt = −1.0710) genes (Sup-
plementary Table 2). The probable explanation for this
divergence is that the MLPA probe and the qPCR primers
map to different regions within the SKI gene. The SKI
gene is mapped between genomic coordinates chr1:2,160,134-
2,241,652 (UCSC Genome Browser, Human February 2009
Assembly); the MLPA probe is mapped between coor-
dinates chr1:2,237,544-2,237,607 (UCSC Genome Browser,
Human February 2009 Assembly) and the qPCR primers are
mapped between coordinates chr1:2,221,777-2,221,861 (UCSC
Genome Browser, Human February 2009 Assembly). Thus,
knowing that this patient presented deletion of ten 1p36
probes distal to the SKI probe (data not shown) and that the
qPCR primers are also located distal to this probe, it is likely
that patient 10 has part of the SKI gene deleted (region of
location of the qPCRprimers) and another part intact (region
of location of the MLPA probe).
From our data it is clear that the qPCR technique using
the two genes, PRKCZ and SKI, was efficient and accurate for
detection of microdeletions associated with monosomy 1p36.
4. Discussion
About 3% of the world population has intellectual disability,
20% to 50% of which is caused by chromosome abnormalities
[23]. One of themost common chromosome abnormalities in
humans ismonosomy 1p36 (OMIM#607872), and it accounts
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for 0.5–0.7% of all cases of idiopathic intellectual disability
[24]. The confirmation of clinical suspicion is essential for
clinical monitoring of the patient and genetic counseling of
the family.
Medical genetics laboratories generally use aCGH for the
diagnosis of monosomy 1p36. However, the high cost of this
test limits its broad adoption, especially in developing coun-
tries [13]. In face of this reality, we found in qPCR technique
the requirements of cost-effectiveness and easy execution
for targeted diagnosis of monosomy 1p36, easily accessible
for low-budget laboratories in developing countries [13–18].
Thus, in this study, we report the development of a qPCR
assay for the detection of copy number changes in the 1p36
region using two target genes, PRKCZ and SKI, which are
deleted in the majority of patients with monosomy 1p36.
The haploinsufficiency of PRKCZ and SKI genes has been
proposed to be related to the neurologic phenotype seen
in patients with monosomy 1p36, thus contributing to the
neurodevelopmental delay [3, 8, 25, 26]. As this feature is
observed in all the patients with monosomy 1p36 [5, 10, 27,
28], we can suggest that these two genes will very likely be
deleted in a majority of patients.
PRKCZ and SKI are located ∼2.0Mb (chr1:1,981,909-
2,116,834) and ∼2.2Mb (chr1:2,160,134-2,241,652), respec-
tively, from the 1p telomere (UCSCGenomeBrowser, Human
February 2009 Assembly), and previous studies have shown
that both genes are within the region where the majority of
1p36 deletions occur.
In one of the first large studies related tomonosomy 1p36,
Heilstedt et al. [5] evaluated the deletion sizes in 61 affected
subjects from 60 families and noticed that, although the
deletion sizes ranged widely, 12.5% of breakpoints clustered
4.0–4.5Mb from the telomere, and 40% of all the breakpoints
occurred 3.0–5.0Mb from the telomere. In a study involving
subtelomeric abnormalities, Ballif et al. [7] analyzed 32
positive individuals for monosomy 1p36 and found that 54%
of the breakpoints were located within the first 5.0Mb from
the 1p telomere and ∼90%were located within the first 10Mb.
D’Angelo et al. [8] detected a large variability in the sizes
of deletions (∼2.0–10Mb) when they analyzed nine patients;
however, all the patients showed deletion of PRKCZ and SKI.
In other studies, performed with a smaller number of
patients, there was also a change in the number of copies
of PRKCZ and SKI in most of affected individuals, which
support our results. Gajecka et al. [29] characterized complex
rearrangements in four individuals with deletions, duplica-
tions, and/or triplications of 1p36 and they compared the
regions of imbalance to two cases published. Results of aCGH
and FISH revealed an overlapping region of 1.1Mb containing
PRKCZ and SKI, which were deleted in four individuals and
duplicated/triplicated in two individuals. Vieira et al. [30]
used aCGH to evaluate one patient that, despite showing a
Smith-Magenis-like phenotype, lacked the 17p11.2 deletion or
amutation inRAI1.They detected a deletion of approximately
2.15Mb in 1p36.32-1p36.33 region containing PRKCZ and
SKI, which resulted in the final diagnosis of monosomy 1p36.
Rosenfeld et al. [3] characterized small interstitial dele-
tions, and they reported five patients with 199–823 kb
overlapping deletions of proximal 1p36.33, three of which
included PRKCZ and SKI. A small interstitial deletion
(1.52Mb) including PRKCZ and SKI was found by Gajecka et
al. [31] during evaluation of two siblingswithmild phenotypic
features of monosomy 1p36. It is important to emphasize that
most of the genes whichwere contained in the smallest region
of deletion (174 kb) characterized by Rosenfeld et al. [3] were
not deleted in the patients analyzed byGajecka et al. [31], with
only one of a total of five genes showing partial deletion and
the others remaining intact. Indeed the specific critical region
for monosomy 1p36 has not been determined yet, greatly
making its study difficult. Really, there does not seem to be
a single critical region for this syndrome.
The qPCR results showed that bothmarkers were efficient
in the identification of patients with 1p36 microdeletions,
resulting in a test with 100% sensitivity and 100% specificity.
With the exception of the result of patient 10 for SKI marker
(subject 10 of Supplementary Table 2), all the qPCR results
were 100% concordant with results previously determined by
aCGH, FISH, and/or MLPA. It is important highlight that
rare patients, who have mainly small and atypical interstitial
microdeletions, might, occasionally, not be identified by
this qPCR assay. However, the qPCR assay presented here
enables the identification of themajority of patients with 1p36
monosomy.
We have calculated that detecting a patient suspected of
having monosomy 1p36 by qPCR would have a final cost
of US$ 8.13. This calculation was done considering only the
necessary reagents for the qPCR reaction.The costs involving
the reagents of other steps, such as DNA extraction, and
the costs of laboratory materials, equipment, and workforce
were not included in this calculation. Moreover, the whole
screening process from the genomic DNA extraction to the
analysis of the qPCR data could be performed in a short time
(about 8 hours).
In summary, the results presented here have proven that
qPCR of PRKCZ and SKI can be a fast, accurate, and cost-
effective diagnostic test for monosomy 1p36.
5. Conclusions
Here we report the development of a simple, rapid, and
inexpensive real-time quantitative PCR (qPCR) assay for
targeted diagnosis of monosomy 1p36.We showed that qPCR
of PRKCZ and SKI can be considered an accurate diagnostic
test for monosomy 1p36, easily accessible for low-budget
laboratories in developing countries.
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